3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid has been researched along with thromboxane b2 in 12 studies
| Studies (3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid) | Trials (3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid) | Recent Studies (post-2010) (3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
|---|---|---|---|---|---|
| 36 | 1 | 1 | 7,483 | 715 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooley, AJ; Frisbie, DD; Grauer, GF; Longhofer, SL | 1 |
| Cooley, AJ; Culham, CA; Frisbie, DD; Grauer, GF; Johnson, HC; Longhofer, SL; Schultz, KT | 1 |
| Culham, CA; Grauer, GF; Johnson, HC; Longhofer, SL; Schultz, KT | 1 |
| Anderson, C; Brunt, E; Jendrisak, M; Mangino, M; Murphy, M; Sicard, G; Tobimatsu, M | 1 |
| Ambler, J; Butler, KD; Ku, EC; Maguire, ED; Smith, JR; Wallis, RB | 1 |
| Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB | 1 |
| Chaland, P; Corman, J; Daloze, P; Douglas, F; Etienne, P; Giroux, L; Moutquin, JM; Smeesters, C; St-Louis, G | 2 |
| Kitzen, JM; Lucchesi, BR; Lynch, JJ; Uprichard, AC; Venkatesh, N | 1 |
| Bennett, WM; Cannon, C; Hefty, DJ; Jasani, MK; Johnston, T; Kubacki, VB; Martin, LL; Rakhit, A; Schaffer, AV; Smith, SR | 1 |
| Grieve, EM; Hawksworth, GM; Simpson, JG; Whiting, PH | 1 |
| Behrend, EN; Fettman, MJ; Getzy, DM; Grauer, GF; Greco, DS; Mani, I; Reinhart, GA | 1 |
12 other study(ies) available for 3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid and thromboxane b2
| Article | Year |
|---|---|
Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs.
Topics: Animals; Antibodies; Concanavalin A; Creatinine; Dog Diseases; Dogs; Glomerular Filtration Rate; Glomerulonephritis; Immune Complex Diseases; Kidney; Male; Proteinuria; Pyridines; Thromboxane B2; Thromboxane-A Synthase | 1992 |
Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Concanavalin A; Dinoprostone; Disease Models, Animal; Dogs; Glomerular Filtration Rate; Glomerulonephritis; Immune Complex Diseases; Kidney; Kidney Glomerulus; Male; Pyridines; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase | 1991 |
Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
Topics: Administration, Oral; Animals; Dogs; Kidney; Male; Pyridines; Thromboxane B2; Thromboxane-A Synthase; Time Factors | 1990 |
Thromboxane synthesis inhibition and renal allograft function.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dogs; Glomerular Filtration Rate; In Vitro Techniques; Kidney; Kidney Transplantation; Pyridines; Renal Circulation; Thromboxane B2; Thromboxane-A Synthase; Transplantation, Autologous; Transplantation, Homologous | 1989 |
CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Topics: Animals; Arachidonic Acids; Arthus Reaction; Blood Coagulation; Blood Platelets; Collagen; Forssman Antigen; Guinea Pigs; Humans; In Vitro Techniques; Pyridines; Rabbits; Radioimmunoassay; Rats; Rats, Inbred Strains; Thrombocytopenia; Thromboxane B2; Thromboxane-A Synthase; Time Factors | 1985 |
Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Cholesterol, Dietary; Cyclooxygenase Inhibitors; Hypercholesterolemia; Imidazoles; Pyridines; Rabbits; Sulfinpyrazone; Thromboxane B2; Thromboxane-A Synthase | 1987 |
Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Creatinine; Cyclosporins; Dinoprostone; Kidney Diseases; Male; Prostaglandins E; Pyridines; Rats; Thromboxane B2; Thromboxane-A Synthase | 1988 |
Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Creatinine; Cyclosporins; Dinoprostone; Kidney; Prostaglandins E; Pyridines; Rats; Thromboxane B2; Thromboxane-A Synthase | 1988 |
Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Topics: Animals; Coronary Disease; Coronary Thrombosis; Death, Sudden; Dogs; Electric Stimulation; Electrodes, Implanted; Electrophysiology; Female; Heart Rate; In Vitro Techniques; Male; Myocardial Infarction; Platelet Aggregation; Pyridines; Tachycardia; Thromboxane B2; Thromboxane-A Synthase; Ventricular Fibrillation | 1988 |
Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
Topics: Adult; Cyclosporine; Glomerular Filtration Rate; Humans; Kidney; Kidney Transplantation; Middle Aged; Pyridines; Thromboxane B2; Thromboxane-A Synthase | 1993 |
The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition.
Topics: Animals; Body Weight; Cyclosporine; Enzyme Inhibitors; Kidney Diseases; Male; Prostaglandins; Pyridines; Rats; Rats, Sprague-Dawley; Thromboxane B2; Thromboxane-A Synthase | 1993 |
Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Topics: Animals; Body Weight; Creatinine; Diet; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Eating; Enzyme Inhibitors; Fatty Acids, Omega-3; Food, Fortified; Gentamicins; Glomerular Filtration Rate; Kidney Cortex; Kidney Diseases; Male; Potassium; Prostaglandins; Protein Synthesis Inhibitors; Pyridines; Random Allocation; Sodium; Thromboxane B2; Thromboxane-A Synthase | 1996 |